Aripiprazole Tablet
Product Images NDC 82804-235

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 13 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 82804-235). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Image 1 (Figure 1)

Image 1 (Figure 1)
A pharmacokinetic chart titled 'The Effect of Other Drugs on Aripiprazole Pharmacokinetics' displaying fold changes and 90% confidence intervals for aripiprazole exposure (AUC and Cmax) influenced by various interacting drugs, including CYP3A4 inhibitors (ketoconazole), CYP2D6 inhibitors (quinidine), CYP3A4 inducers (carbamazepine), gastric acid blockers (famotidine), and other drugs such as valproate, lithium, and lorazepam.*
FDA Label Image

Image 2 (Figure 2)

Image 2 (Figure 2)
A scatter plot graph titled 'The Effect of Other Drugs on Dehydro-Aripiprazole Pharmacokinetics' showing fold change and 90% confidence intervals for AUC and Cmax values of dehydro-aripiprazole relative to reference. The chart lists various interacting drugs such as CYP3A4 inhibitor ketoconazole, CYP2D6 inhibitor quinidine, CYP3A4 inducer carbamazepine, gastric acid blockers famotidine, and others including valproate, lithium, and lorazepam, with their effects on pharmacokinetic parameters plotted along a horizontal scale ranging from 0.5 to 3.0 fold change.*
FDA Label Image

Image 3 (Figure 3)

Image 3 (Figure 3)
A pharmacokinetic effect chart titled 'The Effect of Aripiprazole on Pharmacokinetics of Other Drugs' showing fold changes and 90% confidence intervals for various drugs including dextromethorphan, warfarin, omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, and escitalopram. The x-axis measures change relative to reference without interacting drug.*
FDA Label Image

Image 4 (Figure 4)

Image 4 (Figure 4)
A chart titled 'Effect of Intrinsic Factors on Aripiprazole Pharmacokinetics' showing fold change and 90% confidence intervals for aripiprazole exposure metrics (AUC and Cmax) across special populations. Factors include CYP2D6 metabolizer status, gender, age, hepatic impairment levels, and severe renal impairment, with changes relative to reference values plotted on the x-axis.*
FDA Label Image

Image 5 (Figure 5)

Image 5 (Figure 5)
A pharmacokinetic chart titled 'Effect of Intrinsic Factors on Dehydro-aripiprazole Pharmacokinetics' showing the fold change and 90% confidence intervals of AUC and Cmax for various intrinsic factors including CYP2D6 metabolizer status, gender, age, hepatic impairment (mild, moderate, severe), and severe renal impairment, plotted against change relative to reference on the x-axis.*
FDA Label Image

Fig-6 (Figure 6)

Fig-6 (Figure 6)
A Kaplan-Meier curve showing the cumulative proportion of patients with relapse over time in days from randomization for a schizophrenia study. The graph compares relapse rates between two groups labeled as 'Aripiprazole' and 'Placebo,' with the aripiprazole group showing a lower proportion of relapse over 182 days. The x-axis displays days from randomization, and the y-axis shows the proportion with relapse, including the number of subjects at risk at various time points.*
FDA Label Image

7 (Figure 7)

7 (Figure 7)
A Kaplan-Meier curve estimating the cumulative proportion of patients with relapse over days from randomization in a bipolar study. The graph compares relapse rates between aripiprazole and placebo groups, with the y-axis showing the proportion with relapse and the x-axis showing days from randomization. The number of subjects at risk is displayed below the x-axis for both groups.*
FDA Label Image

8 (Figure 8)

8 (Figure 8)
A Kaplan-Meier curve illustrating the cumulative proportion of patients experiencing relapse to any mood event over 364 days. The chart compares aripiprazole and placebo groups, plotting proportion with relapse on the vertical axis and days from randomization on the horizontal axis. The number of subjects at risk is indicated below the time axis.*
FDA Label Image

9 (Figure 9)

9 (Figure 9)
A line graph showing the least square means of change from baseline in YGTSS total tic score over 8 weeks of treatment. The graph compares three groups: aripiprazole low dose, aripiprazole high dose, and placebo. The y-axis represents the mean change in YGTSS total tic score, and the x-axis represents weeks of treatment.*
FDA Label Image

82804-235-90 (Image 01)

82804-235-90 (Image 01)
Label for aripiprazole 5 mg tablets by Proficient Rx LP. The label states 90 tablets per container with each tablet containing 5 mg of aripiprazole. Tablets are described as white to off-white, round, uncoated, debossed with '5' on one side and '17' on the other. Manufacturer is Torrent Pharmaceuticals Ltd., India. The label includes the NDC 82804-235-90 and storage instructions.*
FDA Label Image
Image (Mg Logo)
FDA Label Image
Logo (Pi Logo)
FDA Label Image

Description Image (Structure)

Description Image (Structure)
Chemical structure diagram of aripiprazole showing the arrangement of atoms and bonds including chlorinated aromatic rings and other structural features.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.